CIAS
VYGR icon

Capital Investment Advisory Services’s Voyager Therapeutics VYGR Stock Holding History

Capital Investment Advisory Services’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-400
Closed -$10K – 1474
2019
Q2 		$10K Buy
+400
New +$9.15K ﹤0.01% 984

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Capital Investment Advisory Services's VYGR Position: Q3 2019 in Review

Capital Investment Advisory Services sold out of Voyager Therapeutics (VYGR) in Q3 2019, closing a stake of 400 shares — an estimated $10K sold.

Capital Investment Advisory Services first reported a position in VYGR in Q2 2019 and held it in 1 quarter. The position peaked at $10K in Q2 2019. 131 funds tracked by Wall St. Rank hold VYGR as of Q3 2019.

  • Capital Investment Advisory Services reported no remaining Voyager Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Capital Investment Advisory Services sold 400 Voyager Therapeutics shares in Q3 2019, an estimated $10K.
  • Capital Investment Advisory Services first reported a position in Voyager Therapeutics in Q2 2019 and held it in 1 quarter.
  • Capital Investment Advisory Services's Voyager Therapeutics position peaked at $10K in Q2 2019.
  • 131 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2019.

Based on Capital Investment Advisory Services's 13F filing for Q3 2019, filed 17 Oct 2019.